J&J dumps $915M de­vel­op­ment deal with Han­mi as an­oth­er Big Phar­ma aban­dons dis­as­ter-prone Ko­re­an drug­mak­er

An­oth­er one of Han­mi’s Big Phar­ma R&D al­liances has end­ed up on the rocks.

To­day it’s J&J’s turn to walk away from the South Ko­re­an phar­ma com­pa­ny, writ­ing off a $105 mil­lion up­front and every­thing else it has spent try­ing to ad­vance a new drug for di­a­betes and obe­si­ty since ink­ing the deal close to 4 years ago.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA